Medtronic Announces Positive Results Of Onyx ONE Clear Study

(RTTNews) - Medtronic plc (MDT) announced positive results of the Onyx ONE Clear Study that evaluated Resolute Onyx DES in high bleeding risk (HBR) patients with one-month dual antiplatelet therapy (DAPT) in the United States and Japan.

The study met its primary endpoint of cardiac death or myocardial infarction by beating a performance goal derived from contemporary one-month DAPT trials at one-year post-procedure.

The Onyx ONE Clear study's primary composite endpoint of cardiac death or myocardial infarction was 7.0%, beating the pre-specified performance goal of 9.7% at one-year post-procedure. The rate of stent thrombosis was low at 0.7% at one year. The performance goal was based on short-DAPT studies.